VIALS (lyophilized powder for infusion): 1. Dosage:
See prescribing information for full details. Prescribing Restrictions:
Prevention of cardiotoxicity in women with breast cancer at high risk of heart failure. receiv. doxorubicin – cont. ther. Contra-Indications:
Hypersensitivity. Should not be used with chemotherapy regimens that do not contain an anthracycline. Special Precautions:
The pharmacokinetics have not been evaluated in pediatric populations, nor in hepatic or renal insufficiency patients. May add to the myelosuppression caused by chemotherapeutic agents, therefore cardiac function should be carefully monitored. Secondary malignancies (primarily acute myeloid leukemia) have been reported in patients treated chronically with oral razoxane. Razoxane is the racemic mixture, of which dexrazoxane is the S(-)-enantiomer. Should be given by slow I.V. push or rapid drip intravenous infusion from a bag. Doxorubicin should not be given prior to the injection of dexrazoxane. Doxorubicin should be given within 30 minutes after beginning the treatment. Patients should be closely monitored. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing should be discontinued during therapy. See prescribing information for full details. Side Effects:
Alopecia, nausea, vomiting, fatigue, malaise, stomatitis, fever, infection, diarrhea, pain on injection, sepsis, neurotoxicity, streaking, erythema. See prescribing information for full details. Drug Interactions:
See prescribing information for full details.